The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey

European Psychiatry

Volumn 24, Issue 3, 2009, Pages 143-148

  Vogel, Friederike ^a   Gansmüller, Reinhard ^a   Leiblein, Thomas ^a   Dietmaier, Otto ^b   Wassmuth, Hans ^b   Gründer, Gerhard ^c   Hiemke, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Klinikum am Weissenhof   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Drug interactions; Plasma concentration; Schizophrenia; Therapeutic drug monitoring; Ziprasidone

Indexed keywords

AMISULPRIDE; BENZODIAZEPINE; BIPERIDEN; CARBAMAZEPINE; CHLORPROTHIXENE; CLOZAPINE; DIAZEPAM; HALOPERIDOL; LEVOMEPROMAZINE; LORAZEPAM; METOPROLOL; MOOD STABILIZER; OLANZAPINE; PAROXETINE; PERAZINE; PROMETHAZINE; PROTHIPENDYL; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ARTICLE; BLURRED VISION; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOOD DISORDER; PRIORITY JOURNAL; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TENSION;

ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MOOD DISORDERS; PIPERAZINES; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THIAZOLES; TREATMENT OUTCOME;

EID: 63449126577     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2008.09.003     Document Type: Article

References (28)

1. Baumann P., Hiemke C., Ulrich S., Eckermann G., Gaertner I., Gerlach M., et al., Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37 (2004) 243-265
2. Beedham C., Miceli J.J., and Obach R.S. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 23 (2003) 229-232
3. Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 38 (2000) 393-414
4. Caley C.F., and Cooper C.K. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother 36 (2002) 839-851
5. Deutschman D.A., and Deutschman D.H. High-dose ziprasidone in treatment-resistant schizophrenia and affective spectrum disorders: a case series. J Clin Psychopharmacol 27 5 (2007 Oct) 513-514
6. Eilers R. Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness. Clin Pharmacokinet 29 (1995) 442-450
7. Farde L., Wiesel F.A., Halldin C., and Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45 (1988) 71-76
8. Hamelin B.A., Allard S., Laplante L., Miceli J., Wilner K.D., Tremblay J., et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy 18 (1998) 9-15
9. Hiemke C., Dragicevic A., Gründer G., Härtter S., Sachse J., Vernaleken I., et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 26 (2004) 156-160
10. Joyce A.T., Harrison D.J., Loebel A.D., Carter C.T., and Ollendorf D.A. Effect of initial ziprasidone dose on length of therapy in schizophrenia. Schizophr Res 83 (2006) 285-292
11. Kane J.M., Khanna S., Rajadhyaksha S., and Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 21 (2006) 21-28
12. Kirschbaum K.M., Müller M.J., Malevani J., Mobascher A., Burchardt C., Piel M., et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry 11 (2007) 1-7
13. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
14. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., and Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 334 (1987) 1-100
15. Mamo D., Kapur S., Shammi C.M., Papatheodorou G., Mann S., Therrien F., et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 161 (2004) 818-825
16. Mauri M.C., Colasanti A., Rossattini M., Volonteri L.S., Dragogna F., Fiorentini A., et al. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels. Pharmacopsychiatry 40 (2007) 89-92
17. Mauri M.C., Volonteri L.S., Colasanti A., Fiorentini A., De Gaspari I.F., and Bareggi S.R. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 46 (2007) 359-388
18. Miceli J.J., Anziano R.J., Robarge L., Hansen R.A., and Laurent A. The effect of carbamazepine on the steady-state pharmacokinetics of Ziprasidone in healthy volunteers. Br J Clin Pharmacol 49 Suppl. 1 (2000) 65S-70S
19. Miceli J.J., Glue P., Alderman J., and Wilner K. The effect of food on the absorption of oral ziprasidone. Psychopharmacol Bull 40 (2007) 58-68
20. Miceli J.J., Wilner K.D., Hansen R.A., Johnson A.C., Apseloff G., and Gerber N. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol 49 Suppl. 1 (2000) 5S-13S
21. Müller M.J., Regenbogen B., Härtter S., Eich F.X., and Hiemke C. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res 41 8 (2007) 673-679
22. National Institute of Mental Health. 12-CGI. Clinical global impressions. In: Guy W. (Ed). EDCEU assessment in psychopharmacology (1970) 217-222 Revised ed. Rockville, Maryland
23. Rosenfield P.J., Girgis R.R., and Gil R. High-dose ziprasidone-induced acute dystonia. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 546-547
24. Sachse J., Härtter S., and Hiemke C. Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection. Ther Drug Monit 27 (2005) 158-162
25. Stahl S.M., and Shayegan D.K. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 64 Suppl. 19 (2003) 6-12
26. Valenstein M., Blow F.C., Copeland L.A., McCarthy J.F., Zeber J.E., Gillon L., et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 30 (2004) 255-264
27. 11C] raclopride. J Clin Psychopharmacol; in press.
28. Weiden P.J., Kozma C., Grogg A., and Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 55 (2004) 886-891